Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled AmBisome for the Prevention of Aspergillus Colonization in Lung Transplant Recipients
NCT01254708Phase 2Suspended
- Sponsor
- University Health Network
- Start
- Jan 2012
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of amphotericin b in Aspergillus colonization and invasive aspergillosis (IA) (2 arms), sponsored by University Health Network. Primary endpoints: Pulmonary Function at 12 months, Symptoms at 12 months and 1 more. Started Jan 2012; status: suspended.
02
Drugs
amphotericin b
03
Conditions
Aspergillus colonizationinvasive aspergillosis (IA)
Beyond the preview
Go deeper on NCT01254708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01254708.